Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1159P - Individualized methylation-based dynamic analysis of cell-free DNA in postoperative monitoring of resected lung cancer

Date

16 Sep 2021

Session

ePoster Display

Topics

Translational Research;  Surgical Oncology

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Kezhong Chen

Citation

Annals of Oncology (2021) 32 (suppl_5): S931-S938. 10.1016/annonc/annonc727

Authors

K. Chen1, G. Kang1, Z. Zhang2, A. Lizaso3, S. Beck4, I. Lyskjær4, O. Chervova4, B. Li2, H. Shen1, C. Wang2, B. Li3, H. Zhao1, S. Chuai2, F. Yang1, N. Kanu5, J. Wang1

Author affiliations

  • 1 Thoracic Surgery, Peking University People’s Hospital, 100044 - Beijing/CN
  • 2 Research And Development, Burning Rock Biotech, Guangzhou/CN
  • 3 Data Science, Burning Rock Biotech, Guangzhou/CN
  • 4 University College London Cancer Institute, University College London, London/GB
  • 5 Cancer Research Uk Lung Cancer Centre Of Excellence,university College London Cancer Institute, University College London, London/GB

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1159P

Background

The feasibility of DNA methylation-based assays in detecting minimal residual disease (MRD) and postoperative cancer surveillance remains unestablished. Our prospective study investigated the dynamic characteristics of cancer-related methylation signals and the feasibility of methylation-based MRD detection in surgical lung cancer patients.

Methods

Matched tumor, tumor-adjacent tissues, and longitudinal blood samples collected from 114 patients (MEDAL cohort) with stage I-IIIA non-small cell lung cancer were analyzed by both ultra-deep targeted sequencing and bisulfite sequencing. A tumor-informed methylation-based MRD (timMRD) model was employed to evaluate the methylation status of each blood sample. Survival analysis was performed in the MEDAL cohort and validated in the independent DYNAMIC cohort.

Results

Baseline timMRD-score was positively correlated with tumor burden and invasiveness reflected as tumor area, pathological stage, and solid nodules. TimMRD-score was significantly correlated with the existence and the abundance of somatic mutations in baseline blood samples. TimMRD-score revealed significant dynamic changes at perioperative periods and was significantly higher among the relapsed patients. Patients with higher timMRD-scores at the first follow-up demonstrated significantly shorter disease-free survival in both the MEDAL cohort (HR:5.02, 95%CI:1.17-21.51; P=0.007) and DYNAMIC cohort (HR: 2.36, 95%CI: 1.06-5.23; P=0.025). TimMRD-score identified all the relapsed patients during follow-up regardless of mutation status in the MEDAL cohort. Integrating methylation and mutation status identified recurrence in 0% (0/34) of the low-risk group, 22.2% (8/36) of the medium-risk group, and 100% (3/3) of the high-risk group at the first follow-up.

Conclusions

The dynamic analysis of the methylation status in peripheral blood provides a promising strategy for postoperative cancer surveillance.

Clinical trial identification

MEDAL Study: NCT03634826; 08/05/2018.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

National Natural Science Funds (grant No. 82072566).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.